Social and geographical factors affecting access to treatment of colorectal cancer: a cancer registry study by Crawford, S Michael et al.
Social and geographical factors affecting
access to treatment of colorectal cancer:
a cancer registry study
S Michael Crawford,
1 Violet Sauerzapf,
2 Robin Haynes,
2 David Forman,
3,4,5
Andrew P Jones
2
ABSTRACT
Objective: Cancer outcomes vary between and within
countries with patients from deprived backgrounds
known to have inferior survival. The authors set out to
explore the effect of deprivation in relation to the
accessibility of hospitals offering diagnostic and
therapeutic services on stage at presentation and
receipt of treatment.
Design: Analysis of a Cancer Registry Database. Data
included stage and treatment details from the ﬁrst
6 months. The socioeconomic status of the immediate
area of residence and the travel time from home to
hospital was derived from the postcode.
Setting: Population-based study of patients resident in
a large area in the north of England.
Participants: 39619 patients with colorectal cancer
diagnosed between 1994 and 2002.
Outcomes measured: Stage of diagnosis and receipt
of treatment in relation to deprivation and distance
from hospital.
Results: Patients in the most deprived quartile were
signiﬁcantly more likely to be diagnosed at stage 4
for rectal cancer (OR 1.516, p<0.05) but less so for
colonic cancer. There was a trend for both sites for
patients in the most deprived quartile to be less likely
to receive chemotherapy for stage 4 disease. Patients
with colonic cancer were very signiﬁcantly less likely to
receive any treatment if they came from any but the
most afﬂuent area (ORs 0.639, 0.603 and 0.544 in
increasingly deprived quartiles), this may have been
exacerbated if the hospital was distant from their
residence (OR for forth quartile for both travel and
deprivation 0.731, not signiﬁcant). The effect was less
for rectal cancer and no effect of distance was seen.
Conclusions: Residing in a deprived area is
associated with tendencies to higher stage at diagnosis
and especially in the case of colonic cancer to reduced
receipt of treatment. These observations are consistent
with other ﬁndings and indicate that access to
diagnosis requires further investigation.
Access to treatment for cancer has been the
subject of detailed policy within the National
Health Service over the past 15 years. This
has been stimulated by comparative studies
which show that survival from cancer within
the UK is inferior to that in comparable
economies within Europe
1 and beyond.
2 This
is particularly true of colonic cancer but
much less so for rectal cancer. A ‘high-reso-
lution’ study in which more detailed infor-
mation about each patient was analysed than
is the case for the main analysis was under-
taken as part of the EUROCARE Project. This
suggested that the discrepancy for colonic
cancer could be ascribed to later stage at
presentation.
3
In Scotland, an association between
reduced survival and rural residence attrib-
utable to more advanced stage at diagnosis
has previously been reported
4 and patients
with colorectal cancer are less likely to
receive radiotherapy if they live in a rural
area.
5 In New Zealand, both living in
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ARTICLE SUMMARY
Article focus
There is evidence that the poorer survival of British
patients’ with bowel cancer is related to more
advanced stage than in similar countries.
- Is this related to the environment in which people
live?
- Are there differences in this regard between
colonic and rectal cancer?
Key messages
Residing in a deprived area is associated with:
- tendencies to higher stage at diagnosis.
- especially in the case of colonic cancer with
reduced receipt of treatment.
Strengths and limitations of this study
- A cancer registry study looks at the whole
population of a deﬁned area and so does not
depend on access to speciﬁc institutions.
- A large number of patients have been studied.
- The patients analysed were diagnosed some
years ago.
- Deprivation indices relate to area of residence
rather than to individuals.
- This is a cross-sectional study so inferences of
causality must be cautious.
Crawford SM, Sauerzapf V, Haynes R, et al. BMJ Open 2012;2:e000410. doi:10.1136/bmjopen-2011-000410 1
Open Access Researcha deprived area of residence and at increased distance
from a cancer centre have been associated with reduced
survival.
6
We have conducted a large study using data from the
Northern and Yorkshire Cancer Registry and Informa-
tion Service (NYCRIS) for patients diagnosed with
common epithelial cancers in the period 1994e2002. In
this, we explored the relationship between measures of
access to transport and medical services and disease-
related outcomes. For all primary sites studied, it was
shown that, after controlling for age, sex and socioeco-
nomic deprivation, the likelihood of receiving radio-
therapy was reduced with increasing travel time to the
nearest radiotherapy hospital, and rectal cancer patients
were less likely to receive chemotherapy if they lived
distant from a hospital providing this treatment.
7 Late
stage of colorectal cancer at diagnosis was associated with
greater travel time to the general practitioner, living in
a rural location and in one without access to community
transport.
8
In this paper, we have investigated the possible joint
effect of deprivation and rural inaccessibility on the
stage of presentation and receipt of active treatment for
colorectal cancer patients in our study. Building on our
previous ﬁndings, we test whether distance to diagnostic
treatment hospitals may interact with area socioeco-
nomic deprivation to amply the disadvantage of those
living furthest from hospital and in the most deprived
areas.
PATIENTS AND METHODS
The process of developing a database appropriate for
geographical analyses from the Registry records has
been described in detail elsewhere.
4 Brieﬂy, for the
purpose of this analysis, we assembled a database of all
patients registered with cancer of the colon or rectum
held by the NYCRIS during the period 1994e2002. This
database included the treatment or treatments delivered
in the period up to 6 months, but usually shorter,
following diagnosis.
Car travel times from the patient’s residence to
healthcare providers were estimated in a geographical
information system (ArcGIS 9.2) using the shortest road
route and average driving speeds along speciﬁc classes of
road. An independent survey of 475 patients attending
cancer clinics in the same study area had already estab-
lished that 87% of patients made the journey by car and
that travel estimates based on the road network and
average speeds were closely related to actual car journey
times reported by patients.
9
Deprivation was determined from the Index of
Multiple Deprivation, an area-level measure associated
with the postcode.
10 We removed the access to services
domain from the Index of Multiple Deprivation scores
so as to eliminate the potential of double counting.
Patients were divided into equal quartiles for deprivation
and for travel time to the closest hospital providing
diagnostic access. Patients were allocated to deprivation
quartiles on the basis of socioeconomic deprivation in
their area of residence and travel quartiles on the basis
of distance of residence from the closest hospital
providing diagnostic and surgical treatment services for
bowel cancer.
Statistical analyses were carried out using the SPSS
V.16 software package. ORs were calculated for the stage
distribution at presentation and for the receipt of treat-
ment. Logistic regression models were ﬁtted to deter-
mine how the covariates of hospital travel time and
deprivation quartile were associated with the likelihood
of receiving treatment or being diagnosed at late stage.
For all models, ORs were estimated across the quartiles
of both deprivation and travel time, with the least
deprived and shortest travel time groups forming the
respective reference categories. To test for synergies
between quartiles of deprivation and travel time, inter-
actions between the two categorical variables were ﬁtted.
In the results tables, ORs from the interactions are
presented for each matching quartile category (ie,
quartile 2 of deprivation by quartile 2 of travel time).
The reference category for these interactions was quar-
tile 1 by quartile 1 of each variable. As age and male sex
had an adverse effect for all the variables that were
studied, all ORs were adjusted for these covariates. In
addition, all ORs for the receipt of treatment were
adjusted for tumour stage.
RESULTS
During the time period studied, there were 39619
colorectal tumours recorded by NYCRIS. From this,
information on residential location was available for
11406 rectal tumours and 16850 colon, making a data
set of potential 28256 records for analysis (71.3% of the
total records). From these, data on stage at diagnosis
were available for 7058 of the rectal cancers (62%
completeness) and 11163 of the colon cancers (66%
completeness). The mean age of patients was 70.3 years
(SE 0.11) and 61.5% were men. Mean drive time to the
nearest hospital was estimated to be 14 min (SE 0.09)
with the longest estimate being 1.5 hr.
Stage at presentation
Table 1 shows that patients with carcinoma of the rectum
who were in the most deprived quartile (n¼2939
patients) were signiﬁcantly more likely to present at
stage 4 than at earlier stages. This relationship was
weaker and less consistent for colonic cancer. There was
no effect of distance on this observation for either
tumour site and no evidence of an interaction between
the two factors.
Treatment
We calculated the odds of receiving any surgical, radio-
therapy or chemotherapy treatment, adjusted to account
for the effects of age, sex and stage at presentation.
Among those with rectal cancer (table 2), there was
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Access to colorectal cancer treatmenta tendency for patients to be less likely to receive any
active treatment with increasing deprivation of their area
of residence, but there was no evidence that increasing
distance reduced the likelihood of treatment. There was
a strong tendency among patients with colonic cancer
residing among the two most deprived quartiles
(n¼8425) to be signiﬁcantly less likely to receive treat-
ment (table 2). Although those outside the most prox-
imal quartile were less likely to receive any treatment,
these differences did not reach statistical signiﬁcance
and there was again no evidence of an interaction
between deprivation and travel time.
When the analysis was made for receiving chemo-
therapy for stage 4 cancer (table 3), colonic patients
living in the most deprived quartile were less than half as
likely to receive the treatment. The trend with depriva-
tion did not reach statistical signiﬁcance for rectal
cancer, and there were no associations with travel and
nor any evidence of interactions. Overall, the impression
is that there is a disadvantage for the quartile of society
residing in the most deprived areas with no real effect of
distance of residence from the treating hospital.
DISCUSSION
We have demonstrated a difference between colonic
cancer and rectal cancer in the proportion of patients
from socioeconomically deprived localities of residence
receiving any treatment. Colorectal cancer is usually
considered as one entity when considering how diag-
nostic services work, but there is a developing body of
evidence that points to a difference between them.
Recent studies addressing the presentation of colo-
rectal cancer have emphasised that features such as
rectal bleeding and microcytic anaemia <10 g/dl iden-
tify a minority of patients.
11 However, Stapley et al
12
found that while presentation with an alarm symptom
such as rectal bleeding is associated with earlier stage,
presentation with mild anaemia (10e12.9 g/dl), which is
likely not to cause symptoms prompting the patient to
seek advice, is associated with more advanced stage and
worse survival. Symptoms are otherwise non-speciﬁc:
weight loss, abdominal pain and altered bowel habit. In
this study, which avoided recall bias by using primary
care records, increasing duration of these was not
associated with advancing stage.
Table 1 ORs (adjusted for age and sex) of being diagnosed at stage 4 rather than stages 1e3 for rectal cancer and colonic
cancer
Main effect: travel Main effect: deprivation
Interaction term: travel 3
deprivation
Rectal
Quartile 1 1 1 1
Quartile 2 0.940 (0.616 to 1.433) 1.072 (0.716 to 1.605) 1.258 (0.739 to 2.140)
Quartile 3 1.314 (0.895 to 1.928) 1.319 (0.900 to 1.932) 0.754 (0.465 to 1.223)
Quartile 4 1.172 (0.819 to 1.677) 1.516* (1.053 to 2.182) 0.868 (0.527 to 1.430)
Colonic
Quartile 1 1 1 1
Quartile 2 0.938 (0.697 to 1.263) 1.156 (0.871 to 1.1535) 1.062 (0.725 to 1.555)
Quartile 3 0.993 (0.750 to 1.315) 1.334* (1.019 to 1.747) 0.997 (0.700 to 1.418)
Quartile 4 0.969 (0.750 to 1.252) 1.157 (0.892 to 1.501) 1.121 (0.770 to 1.633)
*p<0.05, 95% CIs shown.
Table 2 ORs of receiving any treatment (adjusted for age, sex and stage) for rectal and colonic cancer
Main effect: travel Main effect: deprivation
Interaction term: travel 3
deprivation
Rectal
Quartile 1 1 1 1
Quartile 2 0.900 (0.547 to 1.482) 0.867 (0.539 to 1.393) 0.898 (0.486 to 1.661)
Quartile 3 0.863 (0.534 to 1.396) 0.712 (0.453 to 1.118) 1.158 (0.646 to 2.075)
Quartile 4 0.987 (0.634 to 1.538) 0.544** (0.343 to 0.838) 1.394 (0.762 to 2.548)
Colonic
Quartile 1 1 1 1
Quartile 2 0.825 (0.559 to 1.216) 0.639* (0.445 to 0.917) 1.476 (0.913 to 2.386)
Quartile 3 0.757 (0.525 to 1.091) 0.603** (0.425 to 0.854) 1.324 (0.847 to 2.068)
Quartile 4 0.810 (0.577 to 1.137) 0.544** (0.390 to 0.760) 0.731 (0.451 to 1.159)
*p<0.05, **p<0.01, 95% CIs shown.
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Access to colorectal cancer treatmentIn a meta-analysis, a weak association of longer delay
and increased survival in colonic cancer was found.
13
This was identiﬁable only after many studies were
excluded for various reasons. In a further analysis, the
same authors showed that there is a tendency for longer
duration of symptoms to be associated with higher stage
in rectal cancer but lower stage in colonic lesions.
14 This
ﬁts with the concept that colonic cancers cause few
major symptoms until the ﬂow of faecal matter is
impeded by an advanced lesion, whereas prompt diag-
nosis following bleeding from rectal cancers permits
successful intervention. This interpretation is supported
by evidence from Denmark, a country with reliance on
primary care, which is similar to that in the UK. In the
presence of alarm symptoms, survival was shown to
decrease with their duration before diagnosis with
a trend to the converse for vague symptoms.
15
A difference between colonic and rectal cancer, which
is consistent with the concept of colonic cancer
presenting later has been described by Møller et al.
16 The
difference in death rates of patients both with colonic
and with rectal cancer was greatest in the ﬁrst month
after diagnosis, more so for colonic cancer. It was
markedly greater in the deprived groups as well as being
strongly related to age. This is entirely consistent with
our ﬁnding that patients from deprived areas are more
likely to have no active treatment, a phenomenon that is
stronger for colonic cancer. However, when death rates
in excess of what is expected in the population occurring
after the ﬁrst month are considered, the disadvantage
for those from a deprived background as well as older
people persists up to 2 years and is stronger for rectal
cancer.
16 Our ﬁnding that for rectal cancer, there is
a greater likelihood of being diagnosed at stage 4 asso-
ciated with deprivation is entirely consistent with this,
reduced likelihood survival to 2 years being associated
with the visceral metastases that deﬁne this stage. Both
tumour sites exhibit a minor trend against the most
deprived patients with stage 4 disease receiving chemo-
therapy. It is most likely that this relates to patients being
too ill to be treated and as such adds detail to the
observations in table 2.
This analysis of observations in colorectal cancer
follows the one previously reported in lung cancer.
17
They differ in that the NYCRIS Database holds adequate
staging information for bowel tumours but not for lung
cancer, whereas in the latter tumour site, attainment of
a histological diagnosis is a variable that reﬂects diag-
nostic activity. The colorectal cancer results show
consistent effects of deprivation, but the effect of
distance of residence from the diagnosing facility that we
saw in lung cancer was not signiﬁcant in this study.
There are consistent effects that apply to the patients
living in the more deprived areas which indicate that in
planning the development of services, it is the needs of
these patients that should be paramount; it seems that
the better off are more able to ﬁnd their own way
through the system. This is supported by the ﬁnding that
patients from deprived backgrounds are more likely to
be admitted to hospital as an emergency
18 and indeed to
have their ﬁrst inpatient episode for this diagnosis as an
emergency admission.
19 On the other hand, increased
demand for diagnostic services will mean that the costs
of investigation of patients who turn out not to have
cancer will increase. They already, it is estimated,
account for 35% of the cost of managing colorectal
cancer.
20
However, the existence of such differences suggests
that there is an avoidable cause for them. It is possible
that people may experience symptoms without recog-
nising that they signify anything of importance; there-
fore, the duration is not recalled and the primary care
physician’s advice is not sought. Encouraging early
results have been obtained from one study of measures
to promote understanding of early symptoms in
deprived communities.
21 To do this requires proactive
approaches to people in such circumstances because
deprived people are not necessarily aware that they have
disadvantages in receiving healthcare.
22 These cancer
sites share the fact that presenting symptoms are
ambiguous.
There are a number of caveats to our ﬁndings. In
order to be comparable to previous work among this
cohort, the analysis was based on data for patients
Table 3 ORs of receiving chemotherapy (adjusted for age and sex) for stage 4 rectal cancer and colonic cancer
Main effect: travel Main effect: deprivation
Interaction term: travel 3
deprivation
Rectal
Quartile 1 1 1 1
Quartile 2 0.702 (0.299 to 1.647) 1.037 (0.463 to 2.319) 1.304 (0.452 to 3.764)
Quartile 3 0.858 (0.402 to 1.833) 0.821 (0.386 to 1.745) 1.143 (0.443 to 3.375)
Quartile 4 1.058 (0.521 to 2.149) 0.732 (0.357 to 1.499) 1.080 (0.416 to 2.806)
Colonic
Quartile 1 1 1 1
Quartile 2 1.310 (0.730 to 2.352) 0.815 (0.465 to 1.429) 0.973 (0.461 to 2.056)
Quartile 3 0.941 (0.540 to 1.639) 0.776 (0.455 to 1.321) 0.991 (0.496 to 1.981)
Quartile 4 1.024 (0.617 to 1.697) 0.454** (0.268 to 0.768) 1.097 (0.521 to 2.314)
**p<0.01, 95% CIs shown.
4 Crawford SM, Sauerzapf V, Haynes R, et al. BMJ Open 2012;2:e000410. doi:10.1136/bmjopen-2011-000410
Access to colorectal cancer treatmentdiagnosed between 1994 and 2002, a period up to almost
a decade ago. In our data set, staging was available for
64.5% of records. In 2009, this ﬁgure stood at 65.1% so
there has been no signiﬁcant improvement in staging
since then.
23 Furthermore, registration personnel
collected data from NHS hospital records, a process that
is not affected by any of the variables affecting access to
care that we have studied. We therefore believe that
there are unlikely to be biases associated with incom-
plete staging. Although pathways from primary care to
diagnosis have not been addressed by any changes in
practice since our patients were diagnosed, future
studies will be need to determine if modiﬁcations to
policy may alter the associations we observed.
Additional limitations include the fact that our study is
cross sectional in nature and therefore we cannot
determine if the associations we have observed are
causal. Furthermore, the large number of statistical
comparisons we have made raises the possibility that
some associations may be due to chance. Our measure of
deprivation was area rather than individual based and we
relied on estimated rather than actual travel times to
hospital, although these estimates have been found to be
accurate in a previous validation study.
9 Nevertheless,
a limitation of our analysis of associations with distance is
that the most distant travel quartile includes a wide
variety of circumstances: the outer suburbs of cities that
host major cancer centres, towns that have no hospital
and the furthest rural locations. In the future, it will be
of interest to evaluate the deﬁciencies in access in each
of these separately.
A new version of the UK Guidance on the diagnosis
and management of colorectal cancer has recently been
developed.
24 It has not addressed those points in the
patient’s pathway that precede referral to a gastrointes-
tinal specialist; our work and other registry studies
indicate that work needs to be done in this area. Timely
diagnosis of cancer when symptoms are non-speciﬁc will
require an increase in the number of patients with such
symptoms undergoing investigation and therefore
consuming more resources. These will especially need to
be deployed in areas of deprivation.
CONCLUSIONS
Patients with large bowel cancer are less likely to receive
a timely diagnosis and to receive active treatment if they
live in a socioeconomically deprived locality. This ﬁnding
is particularly strong for colonic cancer. These ﬁndings
add to the evidence that colonic and rectal cancer differ
in their presentation and that these differences affect
the outcome. They support the view that patients in
different circumstances differ in the way they are able to
access diagnosis and treatment.
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